EGFR and colorectal cancer: Indeed, activating mutations in exon 20 of PIK3CA (3% of all colorectal cancer) may predict clinical resistance to anti-EGFR monoclonal antibodies, but the correlation is not strong enough to be applied as a routine negative predictive marker.